SCHEMBL17450141

SCHEMBL17450141

CC(C)n1cnc2c(NCc3ccccc3)nc(NC(=O)OC(C)(C)C)nc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 11/20 0.72
CCNE1 P24864 8/20 0.72
CCNE2 O96020 1/20 0.72
CCNA2 P20248 1/20 0.72
CCNA1 P78396 1/20 0.72
TDP1 Q9NUW8 2/20 0.70
KDM4E B2RXH2 1/20 0.70
NPC1 O15118 1/20 0.70
MAPT P10636 1/20 0.70
CDK1 P06493 16/20 0.67
CDK5 Q00535 9/20 0.67
CSNK1D P48730 1/20 0.65
CLK2 P49760 1/20 0.65
DYRK1A Q13627 1/20 0.65
HIPK4 Q8NE63 1/20 0.65
SRPK1 Q96SB4 1/20 0.65
CLK4 Q9HAZ1 1/20 0.65
CCNB1 P14635 6/20 0.64
CDK7 P50613 6/20 0.64
CCNH P51946 5/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17004030 0.82 CDK1 (0.80) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL17004020 0.82 CDK1 (0.80) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL17004017 0.81 CDK2 (0.85) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL2097192 0.80 CDK1 (1.00) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL1216848 0.80 CDK1 (1.00) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL1214567 0.80 CDK1 (1.00) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL30848443 0.80 CCNE2 (0.73) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL30848442 0.80 CCNE2 (0.73) CDK2CCNE1CCNE2CCNA2CCNA1
SCHEMBL3082573 0.79 CDK1 (1.00) CDK2CCNE1CCNE2CCNA2CCNA1
Ethane SCHEMBL1218446 0.79 CDK2 (0.86) CDK2CCNE1CCNE2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10519160-B2 Imaging agents for neural flux THE GENERAL HOSPITAL CORPORATION (US) 2019-12-31 US disclosed
WO-2016011394-A1 IMAGING AGENTS FOR NEURAL FLUX THE GENERAL HOSPITAL CORPORATION (US) 2016-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10519160-B2 Imaging agents for neural flux SLC18A2, SLC18A3, PMP22 CDK2 3061/4885CCNE1 3918/4885CCNE2 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.